EGFR and colorectal carcinoma: Other preclinical studies showed that simultaneous targeting of EGFR and mTOR with the tyrosine kinase inhibitor erlotinib and rapamycin, respectively, inhibited the activation of the PI3K/AKT/mTOR signalling pathway, resulting in the inhibition of cell proliferation and cell cycle progression in colorectal carcinoma cells22,40.